Jeremy Lack is an experienced legal professional currently serving as the Director & General Counsel at InnovADR, specializing in Appropriate Dispute Resolution (ADR) investment services. Jeremy has held roles such as Ombudsperson at the Drugs for Neglected Diseases initiative and Counsel at Helvetica Avocats. As a Door Tenant at Quadrant Chambers, Jeremy focuses on mediation and international commercial ADR. An independent attorney-at-law and ADR neutral at LAWTECH.CH, Jeremy facilitates conflict resolution and commercial transactions. Past positions include General Counsel for SonarSource and MindMaze, and faculty lecturer at EPFL on Intellectual Property business strategies. Jeremy has also contributed to various organizations, including the Global Pound Conversation as Series Coordinator, and has advised Charles Russell Speechlys LLP on intellectual property and dispute resolution. Jeremy holds multiple advanced degrees in law from institutions including King's College London and Oxford University.
This person is not in any teams
This person is not in any offices
Drugs for Neglected Diseases initiative - DNDi
2 followers
The Drugs for Neglected Diseases initiative (DNDi) is an international, not-for-profit research and development organization. We discover, develop, and deliver treatments for neglected patients around the world. Our treatments are affordable and patient-friendly – and have already saved millions of lives. We are researching new treatments for people living with Chagas disease, sleeping sickness (human African trypanosomiasis), leishmaniasis, filarial infections, mycetoma, paediatric HIV, hepatitis C, and dengue. Together with our partners, we are working on over 40 projects, including more than 20 new chemical entities. We are also running over 20 clinical trials. When the medical humanitarian organization Médecins Sans Frontières (MSF) won the Nobel Peace Prize in 1999, they dedicated a portion of the award to addressing this fatal imbalance and exploring a new, alternative, not-for-profit model for developing drugs for neglected patients. As a result in 2003, MSF, the World Health Organization, and five international research institutions founded DNDi.